Y. Yanagita

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04)

Masakazu Toi, SJ Lee, Shoichiro Ohtani et al. · Cancer Research · 2016 · 45 citations

Medicine, Oncology, Pharmacology +17

Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)

Masahiro Takada, Hiroshi Ishiguro, Shigenori E. Nagai et al. · Breast Cancer Research and Treatment · 2014 · 37 citations · Full text

Medicine, Oncology, Breast Oncology +16

Molecular analysis of the h-warts/LATS1 gene in human breast cancer.

Nobuhiro Morinaga, Yoshinori Shitara, Y. Yanagita et al. · International Journal of Oncology · 2000 · 31 citations

Medicine, Genetics, Molecular Genetics +15

Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-beta type II receptor gene in sporadic human breast cancers.

Seiichi Takenoshita, Akira Mogi, M Tani et al. · Oncology Reports · 1998 · 28 citations

Medicine, Genetics, Molecular Genetics +11